Multiple Sclerosis, or MS, is a disease that damages the sheaths of nerve cells in the spinal cord and brain. This progressive disease causes symptoms such as severe fatigue, numbness, blurry vision, and impairment to muscular coordination and speech. According to statistics noted in Healthline (http://nnw.fm/4vxzM), multiple sclerosis is now the most widespread disabling neurological condition in young adults around the world.
Furthermore, the Multiple Sclerosis Foundation now estimates that approximately 2.5 million people around the world have MS, with over 400,000 of these cases being in the U.S. Despite research being underway, the cause of MS is still not fully understood. In addition to the above, multiple sclerosis has been proven to be more prominent in women, with the ratio of women with MS to men with MS being about 2 to 1.
Currently, there is no cure for multiple sclerosis, but the treatments focus on speeding recovery from attacks, generally managing symptoms, and slowing the progression of the disease. Among the most commonly prescribed medications to treat MS are beta interferons, which are injected into a muscle or under the skin and reduce the severity and the frequency of relapses.
With this in mind, RegenRX Biopharmaceuticals, Inc. (OTCQB: RGRX), a clinical stage biopharmaceutical company focused on tissue protection, repair, and regeneration, has been developing RGN-352, an injectable Thymosin beta 4 formulation for the treatment of cardiac damage stemming from post-acute myocardial infarction (MI), chronic heart failure, and a variety of nervous system pathologies, including MS.
The drug successfully completed phase 1 clinical trials in 80 healthy subjects using an acute dose regimen. The preclinical studies showed Thymosin beta 4’s potent regenerative and protective effect on the central and peripheral nervous systems. RGN-352 increased the production of oligodendrocyte precursor cells by more than 200%.
In addition, the compound doubled the rate of oligodendrogenesis in the brain, reduced inflammatory infiltrates adjacent to brain vessels by 30%, and restored neurological function by 50%. Most recently, the company announced that it received a notice of acceptance for a patent from the Australian Patent Office for the use of Thymosin beta 4 for myelinate damaged neurons or axons.
For more information, visit www.RegeneRX.com
About NetworkNewsWire
NetworkNewsWire (NNW) provides news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of journalists and writers, NNW is uniquely positioned to best serve private and public companies who need to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
For more information, visit https://www.NetworkNewsWire.com
Please see full disclaimers on the NetworkNewsWire website: http://nnw.fm/Disclaimer
No comments:
Post a Comment